Drug intelligence / Profile preview

clopidogrel

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

Clopidogrel is a thienopyridine-class antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is a prodrug that requires metabolic activation by the cytochrome P450 system, specifically the CYP2C19 enzyme, to produce its active thiol metabolite. This active metabolite irreversibly inhibits the P2Y12 subtype of adenosine diphosphate (ADP) receptors on platelet membranes. By blocking these receptors, clopidogrel prevents the activation of the glycoprotein IIb/IIIa receptor complex, thereby inhibiting platelet aggregation for the remainder of the platelet's lifespan. It is a cornerstone of dual antiplatelet therapy (DAPT), typically administered alongside aspirin, for patients undergoing percutaneous coronary intervention (PCI) or those with acute coronary syndrome (ACS).

Brand names
PlavixIscover
Other names
clopidogrel bisulfateclopidogrel hydrogen sulfate
02

Targets

P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on clopidogrel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clopidogrel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call